Go Pro
→ Trump’s “new Petrodollar” exposed (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$10.01
-0.3%		C$9.72
C$5.66
▼
C$10.17
C$983.30M-0.29093597,635 shs44,902 shs
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
$16.60
$16.60
$14.90
▼
$25.40
$141.07M1.7115,071 shsN/A
VBI Vaccines Inc. stock logo
VBV
VBI Vaccines
C$0.00
C$3.85
▼
C$7.60
C$308.86MN/A3,637 shs1,300 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
+3.83%+4.69%+7.49%+16.61%+55.18%
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
0.00%0.00%0.00%0.00%0.00%
VBI Vaccines Inc. stock logo
VBV
VBI Vaccines
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$10.01
-0.3%		C$9.72
C$5.66
▼
C$10.17
C$983.30M-0.29093597,635 shs44,902 shs
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
$16.60
$16.60
$14.90
▼
$25.40
$141.07M1.7115,071 shsN/A
VBI Vaccines Inc. stock logo
VBV
VBI Vaccines
C$0.00
C$3.85
▼
C$7.60
C$308.86MN/A3,637 shs1,300 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
+3.83%+4.69%+7.49%+16.61%+55.18%
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
0.00%0.00%0.00%0.00%0.00%
VBI Vaccines Inc. stock logo
VBV
VBI Vaccines
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
3.00
BuyC$9.50-5.09% Downside
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
1.95
Reduce$16.60N/A
VBI Vaccines Inc. stock logo
VBV
VBI Vaccines
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$547.31M1.80C$2.60 per share3.85C$8.13 per share1.23
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/AN/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBV
VBI Vaccines
C$3.36M0.00N/AN/AC$1.01 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
-C$30.73MC$0.1566.73N/A2.72%1.91%0.51%N/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/AN/AN/AN/AN/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBV
VBI Vaccines
N/A-C$0.97N/AN/AN/AN/AN/AN/AN/A

Latest VBV, THCX, and GUD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
N/A-C$0.03N/A-C$0.03N/AC$143.97 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
N/AN/AN/AN/AN/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
$0.724.34%N/AN/AN/A
VBI Vaccines Inc. stock logo
VBV
VBI Vaccines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
4.29
2.28
1.79
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/AN/AN/A
VBI Vaccines Inc. stock logo
VBV
VBI Vaccines
14.29
2.64
2.54

Institutional Ownership

CompanyInstitutional Ownership
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
22.75%
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/A
VBI Vaccines Inc. stock logo
VBV
VBI Vaccines
N/A

Insider Ownership

CompanyInsider Ownership
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
45.62%
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/A
VBI Vaccines Inc. stock logo
VBV
VBI Vaccines
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
72598.23 millionN/ANot Optionable
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/A8.50 millionN/ANot Optionable
VBI Vaccines Inc. stock logo
VBV
VBI Vaccines
2264.08 millionN/ANot Optionable

Recent News About These Companies

VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of ...
January 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20230906245918/en/VBI-Vaccines-Partner-Brii-Biosciences-Announces-Topline-Interim-Results-of-Phase-2-Study-Evaluating-BRII-179-VBI-2601-in-Combination-With-PEG-IFN%CE%B1-for-the-Treatment-of-Chronic-Hepatitis-B
Decades of research push cytomegalovirus vaccine closer to reality
January 7, 2025  |  msn.comhttps://www.msn.com/en-gb/science/biology/decades-of-research-push-cytomegalovirus-vaccine-closer-to-reality/ar-AA1x4Xzj
Five Covid-19 vaccine false theories - debunked
October 26, 2024  |  bbc.co.ukhttps://www.bbc.co.uk/bitesize/articles/zgfgf82
VBIVQ VBI Vaccines Inc.
August 15, 2024  |  seekingalpha.comhttps://seekingalpha.com/symbol/VBIVQ
VBI Vaccines Inc. (Nasdaq: VBIV) Rises from the Ashes and is NASDAQ Top Percentage Gainer
August 6, 2024  |  investorideas.comI
VBI Vaccines Starts Restructuring Procedure in Canada
July 30, 2024  |  marketwatch.comhttps://www.marketwatch.com/story/vbi-vaccines-starts-restructuring-procedure-in-canada-233f44fd
VBI Vaccines secures court protection as it restructures, seeks buyer(s)
July 30, 2024  |  fiercebiotech.comF
VBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023
April 16, 2024  |  msn.comhttps://www.msn.com/en-us/money/companies/vbiv-stock-earnings-vbi-vaccines-beats-eps-misses-revenue-for-q4-2023/ar-BB1lJ9ET
VBI Vaccines sells hepatitis B vaccine candidate, manufacturing digs to partner Brii Biosciences for up to $33 million
February 14, 2024  |  fiercepharma.comF
The Truth About Vaccines
January 6, 2024  |  webmd.comW
VBI Vaccines Inc VBIV
October 31, 2023  |  morningstar.comM
Access to new Covid-19 vaccines delayed for Vermonters on Medicaid
September 27, 2023  |  vtdigger.orgV
No, Pfizer COVID-19 vaccine doesn't cause 'VAIDS.' That's not a real condition | Fact check
September 26, 2023  |  usatoday.comhttps://www.usatoday.com/story/news/factcheck/2023/09/16/no-pfizers-covid-19-vaccine-doesnt-cause-vaids-fact-check-children/70865407007/
Availability of new 2023–2024 COVID-19 vaccine in Virginia
September 26, 2023  |  newsleader.comN
The Consumer’s Guide to RSV Vaccines for Older Adults
September 24, 2023  |  everydayhealth.comE
Updated COVID-19 vaccine recommended for everyone; old, young, immunocompromised will benefit most
September 23, 2023  |  usatoday.comhttps://www.usatoday.com/story/news/health/2023/09/12/updated-covid-vaccine-recommended-for-everyone/70826460007/
Is It Safe to Get Multiple Vaccines at the Same Time?
September 22, 2023  |  everydayhealth.comE
The real data behind the new COVID vaccines the White House is pushing
September 21, 2023  |  nypost.comN
New COVID vaccines will be available in RI. Here's how to get one.
September 20, 2023  |  providencejournal.comP
COVID vaccine pill that kills virus before it infects the body could be coming
September 15, 2023  |  nypost.comN

Media Sentiment Over Time

Knight Therapeutics stock logo

Knight Therapeutics TSE:GUD

C$10.01 -0.03 (-0.30%)
As of 04:00 PM Eastern

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca.

AXS Cannabis ETF stock logo

AXS Cannabis ETF NYSEARCA:THCX

$16.60 0.00 (0.00%)
As of 03/1/2024

The Cannabis ETF (THCX) is an exchange-traded fund that is based on the AXS Cannabis index. The fund tracks an index of legal cannabis companies selected and weighted by market capitalization. The fund primarily holds North American companies but may also invest in other countries. THCX was launched on Jul 9, 2019 and is managed by AXS Investments.

VBI Vaccines stock logo

VBI Vaccines TSE:VBV

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas